What's Winning in 2022? 3 Stocks That Are Doing Fine
It's been an ugly year in the stock market in 2022, and most investors are deep in the red. For instance, Immunocore (NASDAQ: IMCR) investors just had a U.S. Food and Drug Administration (FDA) approval, and that stock has shot higher with a 30% gain this year. Will Axsome Therapeutics (NASDAQ: AXSM) be the next stock to pop?